参考资料:[1] Merck Q1 2024 Earnings. Retrieved May 1, 2024, from https://s21.q4cdn.com/488056881/files/doc_financials/2024/q1/Q1-2024-Merck-Earnings-Deck-FINAL.pdf[2] Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. Retrieved May 1, 2024, from https://www.merck.com/news/merck-announces-phase-3-keynote-811-trial-met-dual-primary-endpoint-of-overall-survival-os-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej/[3] Janjigian et al., (2023). Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. The Lancet, DOI:https://doi.org/10.1016/S0140-6736(23)02033-0[4] Bray et al., (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21834[5] Han et al., (2024). Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center. https://doi.org/10.1016/j.jncc.2024.01.006